Skip to content

The efficacy and safety of milled PEEK(Polyetheretherketone) implant for facial bone reconstruction

The efficacy and safety of milled PEEK(Polyetheretherketone) implant for Facial bone reconstruction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0007176
Enrollment
10
Registered
2022-04-12
Start date
2022-04-18
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : For those who need reconstruction due to bone defects diagnosed by CT (or MRI) (facial bone defects refer to bone defects in skulls (facial bones), orbital bones, and cheekbones, and

Sponsors

The Catholic University of Korea, St. Vincent's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: selection criteria 1. Adult men and women over 19 and under 75 2. Those who need reconstruction and want reconstruction due to bone defects in the face diagnosed by CT (or MRI) (Facial bone defect refers to bone defects in the skull (forehead), orbital bone, and cheekbones, and even if the cause of facial asymmetry after trauma and tumor surgery is bone potential, the insufficient portion is bone defects compared to the normal side. 3.Who agreed to replace and support the defect site with PEEK Patient Specific Implant (PRIMARY-P) developed by CusMedi Co., Ltd. 4. In the case of women, those who have agreed to contraception during the clinical trial period (6 months or more after surgery) 5. Those who agree to participate in clinical trials (subjects and/or agents) and are able to visit for scheduled observations during clinical trials

Exclusion criteria

Exclusion criteria: exclusion criterion 1. If there is a serious infectious disease under the judgment of the examiner. 2. If there is an infectious disease in the surgical site and other surrounding areas under the judgment of the testee, 3. Those with unregulated metabolic diseases (e.g., diabetes, osteomalacia, thyroid disease) 4. A person who is or is planning to take a drug that may affect bone metabolism 5. Patients with immature skeletal structure 6. Persons with severe heart disease or severe liver dysfunction 7. Those with infectious diseases at risk of recurrence 8. Those with blood diseases (leukemia, hemophilia, septicemia, etc. 9. Those who have received radiation therapy at surgical sites 10. Those who have hemorrhagic diseases or need anticoagulants 11. Those who are allergic to implant materials 12. Person who is substance abuse or alcoholics 13. Smokers 14. Pregnant or lactating women who are positive for pregnancy tests performed during screening 15. Other cases where the tester determines that participation in clinical trials is inappropriate because it may affect the results of other, ethical or clinical trials.

Design outcomes

Primary

MeasureTime frame
safety

Secondary

MeasureTime frame
efficacy : achievement of tissue reconstruction;efficacy: patient satisfaction

Countries

Korea, Republic of

Contacts

Public ContactDong Yeon Kim

The Catholic University of Korea, St. Vincent's Hospital

prsdykim@catholic.ac.kr+82-31-249-8887

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026